Treatment of Bone Sarcoma
[Abridged]
Mr E Stanley Lee (Westminster Hospital, London SWI) Osteosarcoma Doubt still exists as to the best treatment of osteosarcoma. Yet the pattern presented by this tumour is on the whole rather stereotyped and predictable, so that it ought to be easy to compare the results of different treatments. About 80% of the patients die, almost always of lung metastases, and these usually become evident (Fig 1) within a few months. A prospective trial of supervoltage radiotherapy, with delayed amputation in cases remaining free from metastases, was instituted at Westminster Hospital in 1951 by my old teacher and colleague Sir Stanford Cade (1951 Cade ( , 1955 . Full details, with results to date, were published in 1964 (Lee & Mackenzie) . The trial continued as a team project until 1965, by which time a total of 187 verified cases had been treated. There were 41 five-year survivors.
For the parents of the child or adolescent with an osteosarcoma, the double tragedy of a major amputation rapidly followed by the appearance of lung metastases can be avoided by this form of management. The plan is always explained to the parents from the start, and, if 8 or 9 months after radiotherapy there are no detectable lung deposits on tomography, the prospect of amputation is greatly cheered by the really good hope of cure. In the less fortunate cases, the child is at least spared a needless and futile mutilation.
The crucial conclusion from this series has been that the five-year survival rate, rather better than 20 %, is about equal to the best obtained in cases treated by urgent surgery, as for example in the Mayo Clinic series (Dahlin & Coventry 1967) . In other words, and this is fundamental, the delay has cost no lives that might have been saved. Those patients destined to develop metastases have already done so by the time the patients present for diagnosis; and our current treatments have no power to alter the outcome. This is scarcely surprising, for these tumours are almost always very large on presentation, and it is rare to see one that could in any sense be called 'early'. We feel we have demonstrated conclusively that, in this disease, there is no virtue in hasty surgery. Dahlin's assumption -'When should amputation be done? As in all operations for malignant tumours, delay is contrary to all known theory and practice' -is invalid. On the other hand, we cannot point to any evidence that our method stimulated any effective immune response by the patients against their tumours, as we had originally hoped might be the case.
Though it is therefore established as perfectly legitimate, given skilled modem radiotherapy, to Boxes show the numbers ofcases detected each month. Curve shows that by 10 months 80% ofthe metastases were manifest 41 defer surgery for a time, we have learned that it is not always desirable. Since 1965 we have allowed ourselves to become somewhat selective in our management. The criterion is whether radiotherapy will give a useful and comfortable limb. This is unlikely if injudicious or careless biopsy has led to fungation of the tumour, if there is flexion contracture of, for example, the hip or knee, or if there is gross pathological fracture. In such cases inmmediate surgery may be the better plan, but these form a small minority.
What happens if surgery is delayed indefinitely? There is no doubt that good radiotherapy can effect total histological destruction of some osteosarcomas as well as clinical healing. But the studies of my colleague Dr Mackenzie suggest that this happens in only about one-third to one-half of the cases, and that in about one-third at least there is recognizable residual tumour that looks viable under the microscopethough this is admittedly an uncertain criterion. Clinical reactivation also can occur, and may be difficult to differentiate from, for example, the effects of injury. We have been mistaken in both directions. Therefore we have not felt justified in postponing surgery longer than about 8 or 9 months from the date of presentation. True, we have a handful of patients from the early days who have survived and remained well without amputation, but this is due to a variety of circumstances, and really despite our policy and recommendation.
Potentiation of radiotherapy: Like other workers, we have sought to increase the tumoricidal effect of the irradiation. We have tried arterial infusion of a cytotoxic drug (mitopodozide) during radiotherapy, also infusion of a hydrogen peroxide preparation in an endeavour to promote oxygenation of the tumour. But we have not been convinced of any benefit. Others have used hyperbaric oxygen with the same idea, and Herman Suit in Houston (Suit & Lindberg 1968) has experimented with and abandoned high dose irradiation (up to 16,000 rads in 16 fractions in 50 days) in limbs rendered anoxic by tourniquet. Up till now, therefore, eventual amputation in cases without metastases must unfortunately still be advised.
Lung metastases: Though usually multiple and fast growing, these occasionally appear late and may be few or even solitary. My colleagues Charles Drew and Peter Jones have resected such deposits in 11 of our osteosarcoma cases. In 2 patients the resection was bilateral. Two patients survive more than five years after resection.
Other Bone Sarcomas Several other tumours have clinical spectra merging with that of osteosarcoma. In Ewing's tumour, irradiation in our hands has almost always given sufficient control of the local disease to make amputation unnecessary. Giant cell tumours, if irremovable surgically, can be cured by radiotherapy; but most would agree that adequate surgery is the correct treatment whenever possible. Chondrosarcomas may be clinically very similar to osteosarcomas, and patients with this type have been treated by us on the same lines as the osteosarcomasthat is, by irradiation and delayed amputation. Of 21 patients treated more than five years ago, 12 remain well, so that the prognosis is distinctly better than with osteosarcoma. All of these patients have had their tumours removed. The numbers are small, but it is interesting to note that in every one of these amputation specimens apparently viable tumour was found. These tumours therefore seem to be relatively radioresistant.
Our attitude regarding the osteosarcoma group may be summed up thus: 'Success' is perhaps too euphemistic a word so long as we are treating disseminated disease by local methods, but we would measure our successsuch as it isby the number of futile amputations avoided, and this was achieved in about half the cases.
In conclusion, I must acknowledge my debt to the rest of the team at Westminster, and expecially to my radiotherapist colleagues, Mr T M Prossor and Dr K A Newton.
